A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema.

ABSTRACT:

Background

Mesenchymal stromal cells (MSCs) may reduce inflammation and promote tissue repair in pulmonary emphysema.

Aim

To study the safety and feasibility of bone marrow-derived autologous (BM-) MSC intravenous administration to patients with severe emphysema.

Design

A phase I, prospective open-label study registered at ClinicalTrials.gov as NCT01306513 Eligible patients had lung volume reduction surgery (LVRS) on two separate occasions. During the first LVRS bone marrow was collected, from which MSCs were isolated and expanded ex vivo After 8 weeks, patients received two autologous MSC infusions 1 week apart, followed by the second LVRS procedure at 3 weeks after the second BM-MSC infusion.

Methods

Up to 3 weeks after the last MSC infusion adverse events we

SUBMITTER: Stolk J 

PROVIDER: S-EPMC4888332 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature